Multiomics Tumor Evolution Model of NSCLC

Recruiting

• Conditions: Non-small Cell Lung Cancer

• Registration Number: NCT05352035
• Lead Sponsor: Peking University People's Hospital

Brief Summary

The purpose of this study is to determine the evolutionary mechanism of early-stage non-small cell lung cancer and establish an accurate prognostic model and a recurrence monitoring system by multiomics analysis, which can be helpful for the individual and whole management of lung cancer patients and improve the overall prognosis.

Detailed Description

Lung cancer is the leading cause of cancer-related death globally. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer and surgery is still the main treatment strategy. This study will determine the evolutionary mechanism of early-stage non-small cell lung cancer and establish an accurate prognostic model and a recurrence monitoring system by multiomics analysis, which can be helpful for the individual and whole management of lung cancer patients and improve the overall prognosis.

Study Timeline

• Study Start: 2022-04-20
• Study First Submitted: 2022-04-23
• Study First Submitted QC: 2022-04-23
• Study First Posted: 2022-04-28
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-27
• Last Update Posted: 2025-04-30
• Primary Completion: 2026-12-31
• Study Completion: 2026-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

1. Age ≥ 18 years old;
2. Early-stage NSCLC patients underwent radical surgical resection;
3. Sufficient tumor tissue and blood sample for study use;
4. Available clinical-pathologic data, imaging data and follow-up date;
5. Written informed consent.

Exclusion Criteria

1. History of other malignant tumors;
2. Evidence of distant metastasis before surgery;
3. Insufficient tumor tissue or blood sample for study use;
4. Clinical-pathologic data, imaging data or follow-up date is not available;
5. Other judgments by the Investigator that the patient should not participate in the study.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Disease-free survival (DFS)	Through study completion, an average of 2 years	Time from randomization to disease recurrence or death from any cause.
Overall survival (OS)	Through study completion, an average of 2 years	Time from randomization to death from any cause.

Secondary Outcome Measures

Name	Time	Method
Relationship between translational biomarkers and clinical outcome	Through study completion, an average of 2 years	To evaluate if the translational biomarkers can be prediction tools for the clinical outcomes.

Trial Locations

Locations (1)

Peking University People's Hospital; 🇨🇳 Beijing, China